PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On October 28, 2020, PTC Therapeutics, Inc. (NASDAQ: PTCT) announced the approval of non-statutory stock options and restricted stock units (RSUs) for 18 new employees. A total of 18,610 stock options and 6,860 RSUs were granted as part of the employees' compensation. The stock options have an exercise price of $51.96 per share and a vesting schedule over four years. The inducement grants align with NASDAQ Listing Rule 5635(c)(4), established to attract new talent within the company.
Positive
- Approval of stock options and RSUs indicates company growth and commitment to talent acquisition.
- Stock options priced at $51.96 reflect the company's stock value, potentially incentivizing employee performance.
Negative
- None.
Details
News Market Reaction – PTCT
The recorded move for PTCT in the trading session of this news was +2.71%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH PLAINFIELD, N.J., Oct. 28, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on October 23, 2020 it approved non-statutory stock options to purchase an aggregate of 18,610 shares of its common stock and 6,860 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation.
The inducement grants were approved by PTC's Compensation Committee on October 23, 2020 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
All stock option awards have an exercise price of
ABOUT PTC THERAPEUTICS, INC.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.
For more information please contact:
Media: Investors: |
Jane Baj Lisa Hayes |
+1 (908) 912-9167 +1 (732) 354 8687 |
View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301162161.html
SOURCE PTC Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.